Baduanjin can enhance the Cardiopulmonary Function of Congestive Heart Failure and Reduce Myocardial Injury

The overall aim is to research the influence of Baduanjin on cardiopulmonary function in patients suffering from congestive heart failure. 110 patients with congestive heart failure in our infirmary were selected and the duration is from January 2018 to January 2020. The sufferers took part in the research. They were selected and arbitrarily allocated to the conventional group and the study group. The conventional group received conventional treatment, and the study group received Baduanjin exercise after the conventional treatment. After 6 mo of treatment, the comparison of cardiac function, pulmonary function, exercise endurance index, serum index and improvement in quality of life of these two were evaluated. After treatment, the indexes of cardiac function; left ventricular ejection fraction, left ventricular end-systolic volume, left ventricular end-diastolic volume, pulmonary function like peak oxygen uptake, anaerobic threshold, oxygen uptake/minute ventilation, slope, exercise endurance like maximum exercise power, maximum exercise time, 6 min walk test, serum tumor necrosis factor-alpha, interleukin-1, interleukin-6, plasma N-terminal probrain natriuretic peptide level and Minnesota living with heart failure questionnaire score of quality of life in the study group were better than those in the conventional group (p<0.05). Baduanjin can effectively enhance the cardiopulmonary function of patients with congestive heart failure, enhance their exercise endurance and intensity, regulate the expression level of serum indicators, and comprehensively improve the quality of life of patients.